Literature DB >> 21663411

Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology.

Isaac Yang1, Seunggu J Han, Michael E Sughrue, Tarik Tihan, Andrew T Parsa.   

Abstract

OBJECT: The tumor microenvironment in astrocytomas is composed of a variety of cell types, including infiltrative inflammatory cells that are dynamic in nature, potentially reflecting tumor biology. In this paper the authors demonstrate that characterization of the intratumoral inflammatory infiltrate can distinguish high-grade glioblastoma from low-grade pilocytic astrocytoma.
METHODS: Tumor specimens from ninety-one patients with either glioblastoma or pilocytic astrocytoma were analyzed at the University of California, San Francisco. A systematic neuropathology analysis was performed. All tissue was collected at the time of the initial surgery prior to adjuvant treatment. Immune cell infiltrate not associated with necrosis or hemorrhage was analyzed on serial 4-μm sections. Analysis was performed for 10 consecutive hpfs and in 3 separate regions (total 30 × 0.237 mm(2)). Using immunohistochemistry for markers of infiltrating cytotoxic T cells (CD8), natural killer cells (CD56), and macrophages (CD68), the inflammatory infiltrates in these tumors were graded quantitatively and classified based on microanatomical location (perivascular vs intratumoral). Control markers included CD3, CD20, and human leukocyte antigen.
RESULTS: Glioblastomas exhibited significantly higher perivascular (CD8) T-cell infiltration than pilocytic astrocytomas (62% vs 29%, p = 0.0005). Perivascular (49%) and intratumoral (89%; p = 0.004) CD56-positive cells were more commonly associated with glioblastoma. The CD68-positive cells also were more prevalent in the perivascular and intratumoral space in glioblastoma. In the intratumoral space, all glioblastomas exhibited CD68-positive cells compared with 86% of pilocytic astrocytomas (p = 0.0014). Perivascularly, CD68-positive infiltrate was also more prevalent in glioblastoma when compared with pilocytic astrocytoma (97% vs 86%, respectively; p = 0.0003). The CD3-positive, CD20-positive, and human leukocyte antigen-positive infiltrates did not differ between glioblastoma and pilocytic astrocytoma.
CONCLUSIONS: This analysis suggests a significantly distinct immune profile in the microenvironment of high-grade glioblastoma versus low-grade pilocytic astrocytoma. This difference in tumor microenvironment may reflect an important difference in the tumor biology of glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663411     DOI: 10.3171/2011.4.JNS101172

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  44 in total

1.  Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells.

Authors:  Gregory J Baker; Maria G Castro; Pedro R Lowenstein
Journal:  J Vis Exp       Date:  2015-11-28       Impact factor: 1.355

2.  Analysis of immunobiologic markers in primary and recurrent glioblastoma.

Authors:  Maryam Rahman; Jesse Kresak; Changlin Yang; Jianping Huang; Wesley Hiser; Paul Kubilis; Duane Mitchell
Journal:  J Neurooncol       Date:  2018-01-04       Impact factor: 4.130

3.  Microfluidics in Malignant Glioma Research and Precision Medicine.

Authors:  Meghan Logun; Wujun Zhao; Leidong Mao; Lohitash Karumbaiah
Journal:  Adv Biosyst       Date:  2018-04-02

4.  Screening genes crucial for pediatric pilocytic astrocytoma using weighted gene coexpression network analysis combined with methylation data analysis.

Authors:  H Zhao; W Cai; S Su; D Zhi; J Lu; S Liu
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

5.  Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia.

Authors:  Xiaofan Guo; Yuan Pan; David H Gutmann
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

6.  Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.

Authors:  Iris Fried; Alex Lossos; Tal Ben Ami; Rina Dvir; Helen Toledano; Myriam Weil Ben Arush; Sergei Postovski; Abed Abu Kuidar; Michal Yalon; Michael Weintraub; Mony Benifla
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

Review 7.  Engineering challenges for brain tumor immunotherapy.

Authors:  Johnathan G Lyon; Nassir Mokarram; Tarun Saxena; Sheridan L Carroll; Ravi V Bellamkonda
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 8.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

Review 9.  Current state and future prospects of immunotherapy for glioma.

Authors:  Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 10.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.